Table 2.
Incidence rates of adverse events by short term use of oral corticosteroids
| Characteristics | Sepsis | Venous thromboembolism | Fractures | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of participants | Users (95% CI)* | Non-users (95% CI)* | No of participants | Users (95% CI)* | Non-users (95% CI)* | No of participants | Users (95% CI)* | Non-users (95% CI)* | |||
| Overall | 5138 | 1.8 (1.7 to 1.9) | 1.0 (0.9 to 1.0) | 13 238 | 4.6 (4.4 to 4.8) | 2.4 (2.4 to 2.5) | 71 443 | 21.4 (21.0 to 21.8) | 14.3 (14.2 to 14.4) | ||
| Age (years): | |||||||||||
| 18-24 | 228 | 0.8 (0.6 to 1.2) | 0.5 (0.4 to 0.6) | 302 | 1.3 (1.0 to 1.8) | 0.7 (0.6 to 0.8) | 6506 | 21.3 (19.8 to 22.9) | 15.0 (14.6 to 15.4) | ||
| 25-34 | 374 | 0.9 (0.7 to 1.2) | 0.5 (0.4 to 0.6) | 915 | 2.1 (1.8 to 2.5) | 1.2 (1.1 to 1.3) | 8388 | 16.5 (15.5 to 17.5) | 11.8 (11.5 to 12.1) | ||
| 35-44 | 695 | 1.0 (0.8 to 1.2) | 0.6 (0.5 to 0.6) | 2425 | 3.4 (3.1 to 3.7) | 1.9 (1.8 to 2.0) | 14 214 | 17.8 (17.1 to 18.6) | 11.9 (11.7 to 12.2) | ||
| 45-54 | 1476 | 1.8 (1.6 to 2.0) | 1.0 (1.0 to 1.1) | 4200 | 5.0 (4.7 to 5.4) | 2.7 (2.6 to 2.8) | 19 654 | 20.9 (20.2 to 21.6) | 13.8 (13.6 to 14.0) | ||
| 55-64 | 2365 | 3.3 (3.0 to 3.6) | 1.8 (1.7 to 1.9) | 5396 | 7.2 (6.8 to 7.7) | 4.1 (3.9 to 4.2) | 22 681 | 27.7 (26.8 to 28.6) | 18.5 (18.2 to 18.8) | ||
| Women | 2218 | 1.7 (1.6 to 1.9) | 0.9 (0.9 to 1.0) | 6384 | 4.7 (4.5 to 5.0) | 2.6 (2.5 to 2.6) | 34 637 | 23.0 (22.5 to 23.6) | 15.0 (14.8 to 15.2) | ||
| Men | 2920 | 1.9 (1.7 to 2.1) | 1.0 (1.0 to 1.1) | 6854 | 4.4 (4.2 to 4.7) | 2.3 (2.3 to 2.4) | 36 806 | 19.6 (19.1 to 20.2) | 13.8 (13.6 to 13.9) | ||
| Race: | |||||||||||
| Non-white | 1706 | 2.0 (1.8 to 2.2) | 1.1 (1.0 to 1.2) | 3826 | 4.6 (4.3 to 5.0) | 2.3 (2.2 to 2.4) | 18 089 | 18.5 (17.8 to 19.3) | 12.0 (11.8 to 12.2) | ||
| White | 3432 | 1.7 (1.6 to 1.9) | 0.9 (0.9 to 1.0) | 9412 | 4.6 (4.4 to 4.8) | 2.5 (2.4 to 2.5) | 53 354 | 22.4 (22.0 to 22.9) | 15.3 (15.2 to 15.5) | ||
*Per 1000 person years at risk.